Familial or acquired thrombophilia: estimated prevalence by population, and incidence and relative risk of incident or recurrent venous thromboembolism by thrombophilia.14,41,–43,46 –59
| . | Prevalence in whites of European ancestry, % . | Incident VTE . | Recurrent VTE . | ||||
|---|---|---|---|---|---|---|---|
| Thrombophilia . | Normal . | Incident VTE . | Recurrent VTE . | Incidence* (95% CI) . | Relative Risk (95% CI) . | Incidence* (95% CI) . | Relative Risk (95% CI) . |
| *per 100,000 person-years | |||||||
| †Heterozygous carriers | |||||||
| ‡Homozygous carriers, relative risk = 80 | |||||||
| §Factor V Leiden or prothrombin G20210A plus either antithrombin, protein C or protein S deficiency | |||||||
| Antithrombin deficiency | 0.02–0.04 | 1–2 | 2–5 | 500 (320, 730) | 17.5 (9.1, 33.8) | 10,500 (3800, 23000) | 2.5 |
| Protein C deficiency | 0.02–0.05 | 2–5 | 5–10 | 310 (200, 470) | 11.3 (5.7, 22.3) | 5,100 (2500, 9400) | 2.5 |
| Protein S deficiency | 0.01–1 | 1–3 | 5–10 | 710 (530, 930) | 32.4 (16.7, 62.9) | 6,500 (2800, 11800) | 2.5 |
| Factor V Leiden† | 3–7 | 12–20 | 40–50 | 150 (80, 260) | 4.3‡ (1.9, 9.7) | 3,500 (1900, 6100) | 1.3 (1.0, 3.3) |
| Prothrombin G20210A† | 1–3 | 3–8 | 15–20 | 350 | 1.9 (0.9, 4.1) | – | 1.4 (0.9, 2.0) |
| Combined thrombophilia§ | – | – | – | 840 (560, 1220) | 46.7 (22.5, 97.1) | 5,000 (2000, 10300) | – |
| Hyperhomocysteinemia | – | – | – | – | – | – | 2.5 |
| Antiphospholipid antibody | – | – | – | – | – | – | 2.5 |
| Factor VIII (> 200 IU/dL) | – | – | – | – | – | – | 1.8 (1.0, 3.3) |
| . | Prevalence in whites of European ancestry, % . | Incident VTE . | Recurrent VTE . | ||||
|---|---|---|---|---|---|---|---|
| Thrombophilia . | Normal . | Incident VTE . | Recurrent VTE . | Incidence* (95% CI) . | Relative Risk (95% CI) . | Incidence* (95% CI) . | Relative Risk (95% CI) . |
| *per 100,000 person-years | |||||||
| †Heterozygous carriers | |||||||
| ‡Homozygous carriers, relative risk = 80 | |||||||
| §Factor V Leiden or prothrombin G20210A plus either antithrombin, protein C or protein S deficiency | |||||||
| Antithrombin deficiency | 0.02–0.04 | 1–2 | 2–5 | 500 (320, 730) | 17.5 (9.1, 33.8) | 10,500 (3800, 23000) | 2.5 |
| Protein C deficiency | 0.02–0.05 | 2–5 | 5–10 | 310 (200, 470) | 11.3 (5.7, 22.3) | 5,100 (2500, 9400) | 2.5 |
| Protein S deficiency | 0.01–1 | 1–3 | 5–10 | 710 (530, 930) | 32.4 (16.7, 62.9) | 6,500 (2800, 11800) | 2.5 |
| Factor V Leiden† | 3–7 | 12–20 | 40–50 | 150 (80, 260) | 4.3‡ (1.9, 9.7) | 3,500 (1900, 6100) | 1.3 (1.0, 3.3) |
| Prothrombin G20210A† | 1–3 | 3–8 | 15–20 | 350 | 1.9 (0.9, 4.1) | – | 1.4 (0.9, 2.0) |
| Combined thrombophilia§ | – | – | – | 840 (560, 1220) | 46.7 (22.5, 97.1) | 5,000 (2000, 10300) | – |
| Hyperhomocysteinemia | – | – | – | – | – | – | 2.5 |
| Antiphospholipid antibody | – | – | – | – | – | – | 2.5 |
| Factor VIII (> 200 IU/dL) | – | – | – | – | – | – | 1.8 (1.0, 3.3) |